The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer

British Journal of Cancer

Volumn 111, Issue 1, 2014, Pages 157-165

  Gujam, F J A ^a   Edwards, J ^b   Mohammed, Z M A ^a   Going, J J ^b   McMillan, D C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

breast cancer; survival; tumour microenvironment; tumour stroma

Indexed keywords

ANTINEOPLASTIC AGENT; CD68 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATORY INFILTRATE; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PRIORITY JOURNAL; STROMA; TRIPLE NEGATIVE BREAST CANCER; TUMOR STROMA;

AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; STROMAL CELLS; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84904091724     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.279     Document Type: Article

References (31)

1. Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD (2011) Prognostic significance of CD8\+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 58(7): 1107-1116.
2. Cirri P, Chiarugi P (2012) Cancer-associated-fibroblasts and tumour cells: A diabolic liaison driving cancer progression. Cancer Metastasis Rev 31(1-2): 195-208.
3. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 30(7): 1073-1081.
4. de Kruijf EM, van Nes JG, Van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA, Mesker WE (2011) Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat 125(3): 687-696.
5. Dekker TJ, van de Velde CJ, van Pelt GW, Kroep JR, Julien JP, Smit VT, Tollenaar RA, Mesker WE (2013) Prognostic significance of the tumorstroma ratio: Validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast Cancer Res Treat 139(2): 371-379.
6. Engels B, Rowley DA, Schreiber H (2012) Targeting stroma to treat cancers. Semin Cancer Biol 22(1): 41-49.
7. Ferlay J, Parkin D, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781.
8. Fridman WH, Galon J, Pages F, Tartour E, Sautès-Fridman C, Kroemer G (2011) Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res 71(17): 5601-5605.
9. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5): 646-674.
10. Health and Consumer Protection Directorate-General (2006) European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. European Communities: Luxembourg. Hu M, Polyak K (2008) Microenvironmental regulation of cancer development. Curr Opin Genet Dev 18(1): 27-34.
11. Huijbers ARA Tollenaar, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, Domingo E, VT Smit, Midgley R, Warren BF, Johnstone EC, Kerr DJ, Mesker WE (2013) The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: Validation in the VICTOR trial. Ann Oncol 24(1): 179-185.
12. Ikpatt O, Ndoma-Egba R, Collan Y (2002) Prognostic value of necrosis in Nigerian breast cancer. Adv Clin Pathol 6(1): 31-37.
13. Kim JB, Stein R, O'Hare MJ (2005) Tumour-stromal interactions in breast cancer: The role of stroma in tumourigenesis. Tumor Biol 26(4): 173-185.
14. Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, Tuppurainen K, Makela J, Karttunen TJ, Makinen MJ (2005) Inflammation and prognosis in colorectal cancer. Eur JCancer 41(17): 2645-2654.
15. Lieubeau B, Heymann MF, Henry F, Barbieux I, Meflah K, Grégoire M (1999) Immunomodulatory effects of tumorassociated fibroblasts in colorectaltumor development. Int J Cancer 81(4): 629-636.
16. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, Tollenaar RA (2007) The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 29(5): 387-398.
17. Mirza AN, Mirza NQ, Vlastos G, Singletary ES (2002) Prognostic factors in node-negative breast cancer: A review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 235(1): 10-26.
18. Mohammed ZM, Edwards J, Orange C, Mallon E, Doughty JC, McMillan DC, Going JJ (2012a) Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis. Histopathology 61(2): 283-292.
19. Mohammed ZM, Going JJ, McMillan DC, Orange C, Mallon E, Doughty JC, Edwards J (2012b) Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. Histopathology 61(4): 675-684.
20. Mohammed ZM, Going J, Edwards J, Elsberger B, Doughty J, McMillan D (2012c) The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 107(5): 864-873.
21. Mohammed ZM, Going JJ, Edwards J, Elsberger B, McMillan DC (2013) The relationship between lymphocyte subsets, hormone status and clinicopathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 109(6): 1676-1684.
22. Mohammed ZM, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E, Doughty JC, Edwards J (2012d) Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 106(2): 383-388.
23. Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA (2012) The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Eur J Surg Oncol 38(4): 307-313.
24. Park J, Richards C, McMillan D, Horgan P, Roxburgh C (2014) The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncoly 25(3): 644-651.
25. Courrech Staal EF, Wouters MW, van Sandick JW, Takkenberg MM, Smit VT, Junggeburt JM, Spitzer-Naaykens JM, Karsten T, Hartgrink HH, Mesker WE, Tollenaar RA (2010) The stromal part of adenocarcinomas of the oesophagus: Does it conceal targets for therapy? Eur J Cancer 46(4): 720-728.
26. Ueno H, Jones AM, Wilkinson KH, Jass JR, Talbot IC (2004) Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut 53: 581-586.
27. Wang K, Ma W, Wang J, Yu L, Zhang X, Wang Z, Tan B, Wang N, Bai B, Yang S, Liu H, Zhu S, Cheng Y (2012) Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. J Thorac Oncol 7(9): 1457-1461.
28. West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, Treanor D, Quirke P, Grabsch H (2010) The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br J Cancer 102(10): 1519-1523.
29. Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N, Kawakami Y (2011) The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol 93(3): 294-300.
30. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7(1): 41-51.
31. Yu H, Pardoll D, Richard J (2009) STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9(11): 798-809.